research The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms
Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.
Search
for
Sort by
Research
150-180 / 1000+ results research THU0301 A Phase II Trial of Retinoids on Lupus Nephritis in A Single Center
Retinoids may help treat lupus nephritis and reduce steroid use.
research Skin physiology in microgravity: a 3-month stay aboard ISS induces dermal atrophy and affects cutaneous muscle and hair follicles cycling in mice
A 3-month stay in space causes skin thinning, disrupts hair growth, and changes muscle-related genes in mice.
research An out-of-lab trial: a case example for the effect of intensive exercise on rhythms of human clock gene expression
Intense exercise at night can delay the body's internal clock gene expression by 2 to 4 hours.
research 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
research The Effects of the Oral Supplementation with a Natural Keratin Hydrolysate (Kera-Diet®) on Hair and Nails: Randomized, Placebo and Benchmark-Controlled Clinical Trial on Healthy Females
Taking Kera-Diet® improves hair and nail health without side effects.
research Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study
Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.
research Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial.
The treatment improved hair growth in people with male pattern baldness.
research Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
Topical finasteride is an effective and safer treatment for male hair loss.
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
research The Critical Roles of Serum/Glucocorticoid-Regulated Kinase 3 (SGK3) in the Hair Follicle Morphogenesis and Homeostasis
SGK3 is essential for proper hair growth and health.
research 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D3 analogue in humans
Topical vitamin D3 does not prevent hair loss from chemotherapy.
research LLLT Part 3: Critically Assessing Recent Published LLLT Device Trials: Limitations, Recommendations, and Conclusions
The review concluded that better studies are needed to prove if Low-Level Laser Therapy devices for hair growth really work.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial
The herbal mix (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) and the 3% Minoxidil solution are equally effective in treating hair loss, but the herbal mix has fewer side effects.
research Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial
Topical 3% minoxidil effectively and safely enhances facial hair in transgender men.
research 181 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates telogen effluvium: Randomized, double-blinded, placebo-controlled trial
Sandalore, a synthetic scent, was found to reduce hair loss and improve hair growth in women with hair shedding issues.
research 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial
Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.
research A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
The herbal extract is as effective and safe as 3% minoxidil for treating hair loss.
research A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia
IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
research Faculty Opinions recommendation of Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
DHEA therapy improved pubic hair growth and psychological well-being in young females with adrenal insufficiency.
research When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Curcuma aeruginosa Roxb. essential oil slows hair-growth and lightens skin in axillae; a randomised, double blinded trial
Curcuma aeruginosa essential oil effectively reduces hair growth and lightens underarm skin.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
Topical 5% minoxidil is safe and effective for treating hair loss in Korean men.
research ISID1077 – Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
research Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial
The oral contraceptive with ethinyl estradiol and chlormadinone acetate is effective in treating moderate acne.